“Being a part of AOP Health, a company whose priority is to help patients with rare diseases, is very motivating. It is gratifying to work in the team of experienced colleagues for the benefit of patients”
Facts & Figures
AOP Health is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Health is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Slovak health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Slovakia occupies a special position among many countries where AOP Health is represented. In this market, the company began its development in 2006. AOP Health Slovakia is a team of around five employees in the Marketing & Sales, and Medical for all three therapeutic divisions.
Vision & Mission
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Health.
Foundation of AOP Health in Vienna
The Orphan Regulation EC no 141/2000
1st Approval of Anagrelide in Europe
European Union Expansion
Prostacyclin Analogues Approval
Renaissance of Interferon (IFNα)
Tetrabenazine Approval in Central Europe
Nabilone Approval in Austria
Start of the PROUD PV Study
Beta-blocker for severe sepsis
Treprostinil and PAH
AOP Health headquarters team in Vienna covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance. Find out more about Science & Innovation at AOP Health in English on the global website.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about cooperation ways with AOP Health using the link below.
Thanks to many years of experience in the provision of complex and individualized treatments, AOP Health gained special expertise and market presence in the field of rare diseases.
Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
From its inception AOP Health's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.